Yuh Sakata

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

Toshiaki Watanabe, Michio Itabashi, Yasuhiro Shimada et al. · International Journal of Clinical Oncology · 2015 · 599 citations · Full text

Japanese Society, Surgical Oncology, Jsccr Guideline Committee +14

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients

Yuh Sakata, Atsushi Ohtsu, N Horikoshi et al. · European Journal of Cancer · 1998 · 564 citations

Medicinal Chemistry, Oncology, Gastrointestinal Oncology +9

Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer

Narikazu Boku, Atsushi Ohtsu, Yasuhiro Shimada et al. · Journal of Clinical Oncology · 1999 · 263 citations

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto et al. · The Lancet Oncology · 2013 · 252 citations

Oncology, Randomised Phase 3, Bevacizumab Versus S-1 +8

Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma

Atsushi Ohtsu, Hideo Baba, Yuh Sakata et al. · British Journal of Cancer · 2000 · 205 citations · Full text